332 related articles for article (PubMed ID: 15282385)
1. Cross tolerance to salbutamol occurs independently of beta2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol.
Lee DK; Jackson CM; Bates CE; Lipworth BJ
Thorax; 2004 Aug; 59(8):662-7. PubMed ID: 15282385
[TBL] [Abstract][Full Text] [Related]
2. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
3. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting beta2-agonist therapy.
Lipworth BJ; Hall IP; Aziz I; Tan KS; Wheatley A
Clin Sci (Lond); 1999 Mar; 96(3):253-9. PubMed ID: 10029561
[TBL] [Abstract][Full Text] [Related]
4. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
Lee DK; Jackson CM; Currie GP; Cockburn WJ; Lipworth BJ
Br J Clin Pharmacol; 2003 Nov; 56(5):494-500. PubMed ID: 14651722
[TBL] [Abstract][Full Text] [Related]
6. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
Haney S; Hancox RJ
Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
[TBL] [Abstract][Full Text] [Related]
7. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Wechsler ME; Kunselman SJ; Chinchilli VM; Bleecker E; Boushey HA; Calhoun WJ; Ameredes BT; Castro M; Craig TJ; Denlinger L; Fahy JV; Jarjour N; Kazani S; Kim S; Kraft M; Lazarus SC; Lemanske RF; Markezich A; Martin RJ; Permaul P; Peters SP; Ramsdell J; Sorkness CA; Sutherland ER; Szefler SJ; Walter MJ; Wasserman SI; Israel E;
Lancet; 2009 Nov; 374(9703):1754-64. PubMed ID: 19932356
[TBL] [Abstract][Full Text] [Related]
8. Rapid onset of tolerance to beta-agonist bronchodilation.
Haney S; Hancox RJ
Respir Med; 2005 May; 99(5):566-71. PubMed ID: 15823453
[TBL] [Abstract][Full Text] [Related]
9. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
Bleecker ER; Yancey SW; Baitinger LA; Edwards LD; Klotsman M; Anderson WH; Dorinsky PM
J Allergy Clin Immunol; 2006 Oct; 118(4):809-16. PubMed ID: 17030231
[TBL] [Abstract][Full Text] [Related]
10. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
11. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.
Bleecker ER; Postma DS; Lawrance RM; Meyers DA; Ambrose HJ; Goldman M
Lancet; 2007 Dec; 370(9605):2118-25. PubMed ID: 18156033
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Palmqvist M; Ibsen T; Mellén A; Lötvall J
Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
[TBL] [Abstract][Full Text] [Related]
13. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
14. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients.
Grembiale RD; Pelaia G; Naty S; Vatrella A; Tranfa CM; Marsico SA
Pulm Pharmacol Ther; 2002; 15(5):463-6. PubMed ID: 12406669
[TBL] [Abstract][Full Text] [Related]
16. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism.
Lipworth BJ; Dempsey OJ; Aziz I
Chest; 2000 Aug; 118(2):321-8. PubMed ID: 10936119
[TBL] [Abstract][Full Text] [Related]
17. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients.
Lötvall J; Langley S; Woodcock A
Respir Res; 2006 Aug; 7(1):110. PubMed ID: 16919161
[TBL] [Abstract][Full Text] [Related]
18. Salbutamol tolerance to bronchoprotection: course of onset.
Stewart SL; Martin AL; Davis BE; Cockcroft DW
Ann Allergy Asthma Immunol; 2012 Dec; 109(6):454-7. PubMed ID: 23176887
[TBL] [Abstract][Full Text] [Related]
19. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
[TBL] [Abstract][Full Text] [Related]
20. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.
Tan S; Hall IP; Dewar J; Dow E; Lipworth B
Lancet; 1997 Oct; 350(9083):995-9. PubMed ID: 9329515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]